NCT05983874View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Hiv
Interventions
BIOLOGICAL

BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage

100µg Month 0 and Month 3

Trial Locations (1)

Unknown

The Amsterdam University Medical Centers, Amsterdam

Sponsors

Collaborators (1)

Polymun Scientific GmbH
All Listed Sponsors
collaborator

3M

INDUSTRY

collaborator

Access to Advanced Health Institute (AAHI)

OTHER

collaborator

Polymun Scientific GmbH

INDUSTRY

lead

International AIDS Vaccine Initiative

NETWORK